drugset / Trial / NCT02556021
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
Timeline
- Start
- 2015-09-22
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 100 mg | Oral |